These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10854555)

  • 21. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
    Boku N; Ohtsu A; Yoshida S; Shirao K; Shimada Y; Hyodo I; Saito H; Miyata Y;
    Jpn J Clin Oncol; 2007 Apr; 37(4):275-81. PubMed ID: 17522103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer.
    Kim R; Nishimoto N; Inoue H; Yoshida K; Toge T
    J Infect Chemother; 2000 Dec; 6(4):222-8. PubMed ID: 11810570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
    Atiq OT; Kelsen DP; Shiu MH; Saltz L; Tong W; Niedzwiecki D; Trochanowski B; Lin S; Toomasi F; Brennan M
    J Clin Oncol; 1993 Mar; 11(3):425-33. PubMed ID: 8445416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
    Li JH; Li B; Jiang HR; Zhong MZ
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):229-31. PubMed ID: 21575526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combination chemotherapy of 5-fluorouracil and cisplatin against advanced gastric cancer.
    Imada T; Sairenji M; Suda T; Yamamoto Y; Amano T; Motohashi H
    Hepatogastroenterology; 1999; 46(25):594-600. PubMed ID: 10228867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group].
    Narahara H; Otani T; Iwanaga T; Okajima K; Katsu K; Sowa M; Kobayashi K; Yasutomi M; Okuno M; Takami M; Ishida T; Yasutake K; Yamamoto H; Taguchi T
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1021-6. PubMed ID: 9644317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
    Poorter RL; Bakker PJ; Fockens P; Taat CW; Bartelsman JF; Veenhof CH
    J Infus Chemother; 1996; 6(2):87-91. PubMed ID: 8809656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
    Papadakou M; Xydakis E; Bonios M; Makropoulou E; Boukis C; Kakavoulis T; Karaliotas C; Panagos G
    J BUON; 2006; 11(3):285-9. PubMed ID: 17309151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma].
    Sasaki K; Hirata K; Denno R; Oikawa I; Mukaiya M; Hiraike N; Yagihashi A; Takasaka H; Katsuramaki T; Yamashiro K; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):959-64. PubMed ID: 9212804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
    Thuss-Patience PC; Kretzschmar A; Krenn V; Dörken B; Reichardt P
    Onkologie; 2003 Feb; 26(1):63-5. PubMed ID: 12624520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
    Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
    Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma.
    Kim YH; Kim BS; Seo JH; Choi CW; Kim JS; Chun HJ; Hyun JH; Kim JS
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):64-8. PubMed ID: 10442365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
    Boku N; Ohtsu A; Nagashima F; Shirao K; Koizumi W
    Jpn J Clin Oncol; 2007 Jul; 37(7):509-14. PubMed ID: 17673469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Oh SY; Kwon HC; Kim SH; Lee S; Lee JH; Graves CA; Camphausen K; Kim HJ
    Chemotherapy; 2012; 58(6):426-34. PubMed ID: 23295255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.